Mee-Yew Chen1, Carl D Kirkwood2,3,4, Julie Bines2,3,5, Daniel Cowley2,3, Daniel Pavlic2, Katherine J Lee2,3, Francesca Orsini2, Emma Watts2, Graeme Barnes2,3, Margaret Danchin2,3,5. 1. a Department of Women's and Children's Health , Dunedin School of Medicine, University of Otago , Dunedin , New Zealand. 2. b RV3 Rotavirus Vaccine Program, Murdoch Childrens Research Institute , Parkville , Victoria , Australia. 3. c Department of Paediatrics , University of Melbourne , Parkville , Victoria , Australia. 4. e Department of Microbiology , La Trobe University , Bundoora , Victoria , Australia. 5. d Royal Children's Hospital , Parkville , Victoria , Australia.
Abstract
BACKGROUND: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand and the burden of rotavirus disease was evident. METHODS:Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord blood and IgA levels in colostrum and breast milk samples collected ∼4 weeks, ∼20 weeks and ∼28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0-5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of vaccine was assessed using linear and logistic regression. RESULTS: Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). CONCLUSIONS: The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or stool excretion following 3 doses of RV3-BB Rotavirus Vaccine administered using either a neonatal or infant schedule in New Zealand infants.
RCT Entities:
BACKGROUND: Maternal antibodies, acquired passively via placenta and/or breast milk, may contribute to the reduced efficacy of oral rotavirus vaccines observed in children in developing countries. This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand and the burden of rotavirus disease was evident. METHODS: Rotavirus specific IgG and serum neutralizing antibody (SNA) levels in cord blood and IgA levels in colostrum and breast milk samples collected ∼4 weeks, ∼20 weeks and ∼28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0-5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of vaccine was assessed using linear and logistic regression. RESULTS: Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). CONCLUSIONS: The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or stool excretion following 3 doses of RV3-BB Rotavirus Vaccine administered using either a neonatal or infant schedule in New Zealand infants.
Authors: Trang V Nguyen; Lijuan Yuan; Marli S P Azevedo; Kwang-Il Jeong; Ana M Gonzalez; Cristiana Iosef; Karin Lovgren-Bengtsson; Bror Morein; Peggy Lewis; Linda J Saif Journal: Vaccine Date: 2005-12-01 Impact factor: 3.641
Authors: K B Phua; F S Lim; Y L Lau; E A S Nelson; L M Huang; S H Quak; B W Lee; Y L Teoh; H Tang; I Boudville; L C Oostvogels; P V Suryakiran; I V Smolenov; H H Han; H L Bock Journal: Vaccine Date: 2009-08-11 Impact factor: 3.641
Authors: M Van Den Driessche; K Peeters; P Marien; Y Ghoos; H Devlieger; G Veereman-Wauters Journal: J Pediatr Gastroenterol Nutr Date: 1999-07 Impact factor: 2.839
Authors: Kate L Graham; Peter Halasz; Yan Tan; Marilyn J Hewish; Yoshikazu Takada; Erich R Mackow; Martyn K Robinson; Barbara S Coulson Journal: J Virol Date: 2003-09 Impact factor: 5.103
Authors: Erin C Davis; Vanessa P Castagna; David A Sela; Margaret A Hillard; Samantha Lindberg; Nicholas J Mantis; Antti E Seppo; Kirsi M Järvinen Journal: J Allergy Clin Immunol Date: 2022-09 Impact factor: 14.290
Authors: Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes Journal: Nat Rev Dis Primers Date: 2017-11-09 Impact factor: 52.329
Authors: Daniel Cowley; Daniel Pavlic; Nada Bogdanovic-Sakran; Karen Boniface; Carl D Kirkwood; Julie E Bines Journal: Hum Vaccin Immunother Date: 2018-05-31 Impact factor: 3.452